http://www.zacks.com/stock/news/256560/5-major-drug-stocks-likely-to-beat-q1-earnings-estimates?cid=CS-ZC-FT-256560
Apr 17, 2017 - 2017 is expected to be a strong year for drug stocks.
0
zc:-7566818902376499009
0
https://www.fool.com/investing/2017/04/14/abbvie-inc-the-bear-case-from-a-bull.aspx?source=iedfolrf0000001
Apr 14, 2017 - AbbVie has a lot of things going for it, but the biotech faces some major risks.
0
fool:-5079840870431114012
0
http://www.zacks.com/stock/news/256244/mylan-down-on-fda-warning-letter-to-manufacturing-facility?cid=CS-ZC-FT-256244
Apr 12, 2017 - Shares of Mylan, Inc. (MYL) dropped 2% after the company received a warning letter from the FDA for its manufacturing facility in India
0
zc:4260524364910262106
0
http://www.zacks.com/stock/news/256054/anths-anth-blisibimod-completes-dosing-in-phase-iii-study?cid=CS-ZC-FT-256054
Apr 11, 2017 - Anthera Pharmaceuticals, Inc. (ANTH) recently announced the completion of dosing in a phase II study, BRIGHT-SC. The study evaluated key pipeline candidate blisibimod for treatment of patients with IgA nephropathy (IgAN).
0
zc:-7681953234060067326
0
http://www.zacks.com/stock/news/254949/kite-pharma-completes-filing-for-car-t-therapy-with-fda?cid=CS-ZC-FT-254949
Apr 03, 2017 - Kite Pharma, Inc. (KITE) announced that it has completed the filing of a rolling submission of the Biologics License Application (BLA) for its lead pipeline candidate, axicabtagene ciloleucel to the FDA.
0
zc:7157173683512305201
0
http://www.zacks.com/stock/news/254929/mylan-receives-crl-for-generic-advair-diskus-from-the-fda?cid=CS-ZC-FT-254929
Mar 31, 2017 - Mylan N.V. (MYL) recently suffered a huge setback when it received a complete response letter from the FDA regarding its ANDA for the generic version of asthma drug Advair Diskus.
0
zc:8824692051330127415
0
http://www.zacks.com/stock/news/254704/amgens-leukemia-drug-accepted-for-priority-review-by-fda?cid=CS-ZC-FT-254704
Mar 30, 2017 - Amgen Inc. (AMGN) recently announced that its supplemental biologics license application (sBLA) for its leukemia immunotherapy, Blincyto, has been accepted for priority review by the FDA.
0
zc:8572305264433867968
0
http://www.zacks.com/stock/news/254462/biotech-stock-roundup-regeneron-tesaro-drugs-approved-vertex-scores-big-in-study?cid=CS-ZC-FT-254462
Mar 29, 2017 - Key updates this week include the FDA approval of Tesaro's (TSRO) PARP inhibitor and Regeneron's eczema drug.
0
zc:1245834151735363641
0
http://www.zacks.com/stock/news/254398/pfizers-arthritis-drug-xeljanz-gets-marketing-nod-in-europe?cid=CS-ZC-FT-254398
Mar 28, 2017 - Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz has received marketing approval in Europe.
0
zc:-1388904922062816794
0
http://www.zacks.com/stock/news/254260/the-fearless-girl-statue-isnt-a-symbol-it-is-an-advertisement?cid=CS-ZC-FT-254260
Mar 28, 2017 - The Fearless Girl statue has taken New York City by storm. However, this statue, which is facing down the Charging Bull, is actually an ad.
59
zc:3699352631435605668
59